Medical nutritional therapy on schizophrenic patient with grade 2 obesity and continued antipsychotic drug use

Andry Kelvianto, Wiji Lestari, Diana Sunardi

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

Abstract

Patients suffering from schizophrenia have an elevated risk for obesity and metabolic syndrome due to multiple factors, including antipsychotic drug consumption. Diet and lifestyle modification remained the firstline modalities for management of obesity in patients with schizophrenia. Metformin has been recommended for preventing weight gain, including for schizophrenic patients with long-term consumption of psychiatric medication.
Original languageEnglish
Title of host publicationSelected conference proceedings of the Nutri Virtual Symposium 2021
Pages33
Volume5
EditionS3
DOIs
Publication statusPublished - 31 May 2022

Publication series

NameWorld Nutrition Journal
ISSN (Print)2580-7013

Keywords

  • schizophrenia
  • obesity
  • energy restriction
  • metformin
  • metabolic syndrome

Fingerprint

Dive into the research topics of 'Medical nutritional therapy on schizophrenic patient with grade 2 obesity and continued antipsychotic drug use'. Together they form a unique fingerprint.

Cite this